Abstract
Breast cancer (BCa) is the leading cause of cancer-related deaths among women. Numerous efforts are being directed toward identifying novel tissue and/or circulating molecular markers that may help clinicians in detecting early-stage BCa patients and in providing an accurate estimation of the prognosis and prediction of response to clinical treatments. In this setting, emerging evidence has indicated Cystatin C (Cyst C), as the most potent endogenous inhibitor of cysteine cathepsins, as a possible useful marker in the clinical management of BCa patients.
| Lingua originale | English |
|---|---|
| pagine (da-a) | 1-8-8 |
| Numero di pagine | 9 |
| Rivista | Expert Review of Anticancer Therapy |
| Stato di pubblicazione | Published - 2020 |